Spero Therapeutics (NASDAQ:SPRO) Insider Esther Rajavelu Sells 40,270 Shares

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 40,270 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the completion of the transaction, the insider directly owned 869,450 shares of the company’s stock, valued at $2,060,596.50. The trade was a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Spero Therapeutics Stock Up 0.2%

Shares of SPRO traded up $0.01 during trading hours on Thursday, hitting $2.67. The company had a trading volume of 280,539 shares, compared to its average volume of 1,568,380. Spero Therapeutics, Inc. has a 52-week low of $0.51 and a 52-week high of $3.22. The stock’s 50 day moving average price is $2.18 and its 200 day moving average price is $2.09. The firm has a market cap of $149.99 million, a P/E ratio of -2.72 and a beta of 1.55.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.35. Spero Therapeutics had a negative return on equity of 120.27% and a negative net margin of 110.35%.The company had revenue of $14.19 million during the quarter, compared to analyst estimates of $11.00 million. On average, research analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Trading of Spero Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. purchased a new position in Spero Therapeutics in the 2nd quarter valued at $43,000. Dimensional Fund Advisors LP purchased a new position in shares of Spero Therapeutics during the 3rd quarter worth approximately $55,000. Quadrature Capital Ltd purchased a new position in Spero Therapeutics in the 2nd quarter valued at about $90,000. Axxcess Wealth Management LLC purchased a new stake in Spero Therapeutics in the 2nd quarter worth approximately $94,000. Finally, Capital Asset Advisory Services LLC purchased a new position in Spero Therapeutics during the second quarter worth about $94,000. Hedge funds and other institutional investors own 25.60% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Wednesday, October 8th. Zacks Research cut shares of Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, October 13th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.00.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.